Assertio Holdings, Inc. To Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
25 juil. 2022 08h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12 juil. 2022 18h47 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Participate in LD Micro Invitational XII Conference
01 juin 2022 08h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., June 01, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE
|
Assertio Holdings, Inc.
Reaffirms Full Year Net Product Sales and Raises Full Year Non-GAAP Adjusted EBITDA Guidance Net Product Sales Up 37% and Non-GAAP Adjusted EBITDA Up 52% Compared to Prior Year Quarter Quarterly...
Assertio Holdings, Inc. to Report First Quarter 2022 Financial Results After the Close of Markets on Monday, May 9, 2022
22 avr. 2022 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2022 financial results...
Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution
31 mars 2022 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 31, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT) and BlinkRx, the leading patient access solution, today announced a collaboration to support...
Assertio Reports Fourth Quarter and Full Year 2021 Financial Results
09 mars 2022 08h30 HE
|
Assertio Holdings, Inc.
$32.2 Million Fourth Quarter Net Product Sales, a 7% Increase from Fourth Quarter 2020 and $109.4 Million Full Year Net Product Sales $17.8 Million Fourth Quarter Non-GAAP Adjusted EBITDA, a 118%...
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results Before the Opening of Markets on Wednesday, March 9, 2022
02 mars 2022 09h05 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 02, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2021...
Assertio Holdings, Inc. to Participate in the H.C. Wainwright BioConnect Virtual Conference
10 janv. 2022 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company’s Chief Executive Officer, Dan Peisert, and...
Assertio Holdings, Inc. Announces the Acquisition of Otrexup® (methotrexate) a Drug Device Combination from Antares Pharma, Inc.
15 déc. 2021 17h35 HE
|
Assertio Holdings, Inc.
Trailing 12 Month Reported Revenues of Otrexup Were $15.5 Million Assertio will Pay Antares $18.0 Million Upfront and an Additional $26.0 Million in Deferred Payments Raises Full Year Net Product...